Page 89 - The clinical aspects and management of chronic migraine Judith Anne Pijpers
P. 89
Type AE 3 Muscle weakness 4 Ptosis 1 Rash 11 Pain at injection side 1 Oedema 10 Haematoma 1 Unknown AE 31 Total
2 2 0 11 2 8 3 28
Withdrawal and botulinum toxin A: a double blind RCT
Supplementary Table 1. Adverse events during the double blind phase (weeks 0-12).
Placebo Botulinum toxin A
59 adverse events, in 52 patients (placebo n =27, botulinum toxin A n = 25)
87
4
